Combination Drug Formulation & Single-Entity Evaluation Support

The Defense Health Agency is seeking support for the development and pricing of fixed-dose combination drugs, with a focus on enabling single-entity evaluation for substitution and pricing purposes. This subcontract aims to facilitate the formulation of combination drugs that can be assessed as if they were individual components, streamlining the process for determining appropriate reimbursement and interchangeability within military healthcare systems. The work requires detailed pharmaceutical development expertise and economic modeling to align with DHA’s standards for drug evaluation and cost efficiency. Performance is expected to be based in San Antonio, Texas, with a response deadline of June 29, 2026. The contract falls under NAICS code 325412, which pertains to pharmaceutical preparation manufacturing, indicating the need for capabilities in drug formulation, stability testing, and regulatory-compliant pricing analysis. While no set-aside type is specified, the solicitation is open to eligible subcontractors capable of delivering scientific and technical services that support DHA’s broader goals for pharmaceutical consistency and fiscal responsibility in troop healthcare.